Full Press Release Details
MORRISVILLE, N.C. , Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta , Chief Operating Officer and Chief Financial Officer, and Jason Adair , Chief Business Officer, will provide an update on the company’s business in a fireside chat at the Wells Fargo 21 st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026 at 8:45 a.m. ET .
Access to this event will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations . A replay of the webcast will be archived on the Company's website for at least 30 days.
About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT ® technology. PRINT enabled the development of YUTREPIA ® (treprostinil) inhalation powder for the treatment of PAH and PH-ILD. The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com .
Contact Information